Prosecution Insights
Last updated: October 25, 2026

Difass International S P A

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Difass International S P A has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 examiner and 1 art unit, with prosecution responsibility concentrated in one channel.

MAYHEW, BRADLEY SCOTT is the busiest examiner, with 1 pending matter. The focused record supports a response strategy tailored to the examiner’s review.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MAYHEW, BRADLEY SCOTT 1 0.0% +0.0%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18841688 COMPOSITIONS COMPRISING BUTYRIC ACID AND GLUCONIC ACID FOR THE TREATMENT OF DISORDERS AND SYNDROMES ASSOCIATED WITH INTESTINAL BARRIER DYSFUNCTIONS AND DYSBIOSIS MAYHEW, BRADLEY SCOTT —

Top Art Units

Art UnitApps
1621 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18841688 COMPOSITIONS COMPRISING BUTYRIC ACID AND GLUCONIC ACID FOR THE TREATMENT OF DISORDERS AND SYNDROMES ASSOCIATED WITH INTESTINAL BARRIER DYSFUNCTIONS AND DYSBIOSIS MAYHEW, BRADLEY SCOTT 1621 §103 Non-Final OA — Pending Aug 27, 2024

Managing Difass International S P A's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Difass International S P A have?

Difass International S P A has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Difass International S P A applications?

Bradley Scott Mayhew has the most, with 1 of Difass International S P A's pending office actions.

What technology area are Difass International S P A's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month